rss
Qual Saf Health Care 2009;18:55-58 doi:10.1136/qshc.2007.024471
  • Original Article

A pilot study testing a medication algorithm to reduce polypharmacy

  1. L A Mistler1,2,
  2. T A Mellman3,
  3. R E Drake1,4
  1. 1
    Department of Psychiatry, Dartmouth Medical School, Hanover, New Hampshire, USA
  2. 2
    VA National Quality Scholars Fellowship Program, VA Medical Center, White River Junction, Vermont, USA
  3. 3
    Department of Psychiatry, Howard University, Washington, DC, USA
  4. 4
    Departments of Community & Family Medicine and of Psychiatry, Dartmouth Medical School, Hanover, New Hampshire, USA
  1. Dr L A Mistler, VA Quality Scholars Program (11Q), VA Medical Center, White River Junction, VT 05009, USA; lisa.a.mistler{at}dartmouth.edu
  • Accepted 11 March 2008

Abstract

Background: Polypharmacy is common in the treatment of persons with severe mental illness, yet it is not an evidence-based practice. To address this, an attempt was made to reduce medications for patients already receiving polypharmacy during an episode of acute psychiatric hospitalization.

Methods: A medication-reduction algorithm was developed , based on the best available evidence regarding indications for and efficacy of medications and principles of collaborative care. A feasibility pilot study was conducted using a matched case-control design for 12 patients treated with the algorithm and 12 patients treated as usual.

Results: The intervention patients were discharged on significantly fewer medications than controls; symptom reduction and length of stay did not differ significantly.

Conclusion: A collaborative approach to reducing polypharmacy may reverse the trend to add medications during hospitalization.

Footnotes

  • Funding: The Dartmouth Medical School Quality Research Grant Program provided LAM with support to present this project as a poster at the Fifth Annual Summer Institute on Evidence Based Practices in San Antonio, TX, 29 June to 1 July 2006.

  • Competing interests: None for the first and third authors; speakers’ bureau for Takeda Pharmaceuticals Limited for the second author.

  • Ethics approval: Ethics approval was obtained from The Dartmouth Medical School and New Hampshire State Committees for the Protection of Human Subjects.

  • Patient consent: Obtained.

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.